OBR Daily Commentary

forumImage

Imfinzi Approved in the US for Extensive-Stage Small Cell lung Cancer

(AstraZeneca) Mar 30, 2020 - AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide plus either carboplatin or cisplatin (platinum-etoposide). The approval by the Food and Drug Administration was based on positive results from the Phase III CASPIAN trial showing Imfinzi in combination with SoC platinum-etoposide demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus SoC alone.

H. Jack West, MD (Posted: March 30, 2020)

quotesThis provides another option that is pretty much a lateral move compared to atezolizumab with chemo in the IMpower133 trial. Both efficacy and tolerability data appear very similar. One modest difference is that the CASPIAN trial gave durvalumab with a chemo regimen of either cisplatin or carboplatin along with etoposide, while the IMpower133 chemo backbone was carbo/etoposide only. Accordingly, for those who routinely favor a cisplatin-containing regimen in extensive SCLC, the FDA approval of the CASPIAN regimen may resonate more for them.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

COVID-19 Poses Special Challenges to Cancer Care

(MedPage Today) Mar 25, 2020 - While having an unprecedented impact on all aspects of the nation's healthcare system, the COVID-19 pandemic created unique circumstances and challenges for cancer care, according to authors of a review from the early U.S. epicenter in metropolitan Seattle. The first confirmed U.S. case of COVID-19 was reported on Jan. 20 in Snohomish County, about an hour north of Seattle. The first COVID-19 death in the country occurred there, as well.

Howard S. Hochster, MD (Posted: March 26, 2020)

quotesThere is no question that SARS-CoV-2 will prove to be a major challenge to all health care providers in the coming weeks. At the Rutgers Cancer Institute of NJ we have moved aggressively to reduce staff and patient exposure by seeing as many follow up visits by Telemedicine video chats. We are calling to pre-screen every patient coming in for possible symptoms or exposure, and screening again at the front door. However, we continue to treat all patients on active therapy at this time as "essential services". We are continuing cancer surgery at this time in the same way. At the moment we are prioritizing patients with cancer diagnosis for treatment as usual, and will continue to do so as long as we have the resources.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Opinion: Trump’s Not A Doctor. He’s Only Playing One On TV. By Ezekiel J. Emanuel and Vinay Prasad

(Washington Post) Mar 23, 2020 - President Trump has been promoting chloroquine, an anti-malarial drug, as “a game changer” in combating the coronavirus, perhaps in combination with the antibiotic Azithromycin. “As the expression goes, ‘What do we have to lose?’ ” Trump asked during Saturday’s media briefing.

Ronald Yanagihara (Posted: March 24, 2020)

quotesShould it not be relatively easy to document how many patients who died of covid19 respiratory failure also happened to have been on chronic hydroxychloroquine for SLE, etc?quotes

Read Article arrow
Add Comment 2 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...